Issue 5, 2014

Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery

Abstract

Hesperadin, an established human Aurora B inhibitor, was tested against cultures of Trypanosoma brucei, Leishmania major, and Plasmodium falciparum, and was identified to be a potent proliferation inhibitor. A series of analogs was designed and tested to establish the initial structure–activity relationships for each parasite. In this study, we identified multiple non-toxic compounds with high potency against T. brucei and P. falciparum with good selectivity. These compounds may represent an opportunity for continued optimization.

Graphical abstract: Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery

Supplementary files

Article information

Article type
Concise Article
Submitted
05 Feb 2014
Accepted
17 Mar 2014
First published
17 Mar 2014

Med. Chem. Commun., 2014,5, 655-658

Author version available

Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery

G. Patel, N. E. Roncal, P. J. Lee, S. E. Leed, J. Erath, A. Rodriguez, R. J. Sciotti and M. P. Pollastri, Med. Chem. Commun., 2014, 5, 655 DOI: 10.1039/C4MD00045E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements